aTyr Pharma Inc (LIFE):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:aTyr Pharma Inc (LIFE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8040
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:53
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ATyr Pharma Inc (ATyr Pharma) is a clinical-stage biotechnology company engaged in the discovery and clinical development of medicines for the treatment of cancer and lung diseases. The company’s ATYR1923 is a clinical-stage product candidate, based on the resokine pathway, which binds to the neuropilin-2 receptor harness immune engagement in interstitial lung diseases and other immune-mediated diseases. It also concentrates on research and development of extracellular functionality of tRNA synthetases. ATyr Pharma also develops drugs for cancer, inflammation, neurodegenerative diseases, and metabolic disorders. The company collaborates with research institutions for its research and development activities. ATyr Pharma is headquartered in San Diego, California, the US.

aTyr Pharma Inc (LIFE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
aTyr Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
aTyr Pharma Raises USD76 Million in Series E Financing 11
aTyr Pharma Raises US$49 Million In Series D Financing 13
Partnerships 14
Pangu BioPharma Renews Agreement with Hong Kong University of Science and Technology 14
aTyr Pharma Enters into Agreement with Hong Kong University of Science and Technology, Scripps Research Institute and Stanford University for Human Proteins Discovery 15
Equity Offering 17
aTyr Pharma Plans to Raise up to USD72 Million in Public Offering of Shares 17
aTyr Pharma Raises USD45.8 Million in Private Placement of Shares, Preferred Shares and Warrants 18
aTyr Pharma to Raise up to USD20 Million in Public Offering of Shares 20
aTyr Pharma Raises USD86.3 Million in IPO of Shares 21
aTyr Pharma Inc – Key Competitors 23
aTyr Pharma Inc – Key Employees 24
aTyr Pharma Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Aug 14, 2018: aTyr Pharma announces second quarter 2018 operating results and provides corporate update 26
May 14, 2018: aTyr Pharma Announces First Quarter 2018 Operating Results, Program Prioritization and Corporate Restructuring 28
Mar 19, 2018: aTyr Pharma Announces Fourth Quarter and Year-End 2017 Operating Results and Provides Corporate Update 29
Nov 14, 2017: aTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate Update 31
Aug 14, 2017: aTyr Pharma Announces Second Quarter 2017 Operating Results and Provides an Update on Innovative Immunology Pipeline 33
May 11, 2017: aTyr Pharma Announces First Quarter 2017 Operating Results 35
Mar 16, 2017: aTyr Pharma Announces Fourth Quarter and Year-End 2016 Operating Results 37
Corporate Communications 39
Oct 15, 2018: aTyr Pharma announces leadership transition 39
Jul 31, 2018: aTyr pharma appoints Jill Broadfoot as chief financial officer 40
Nov 01, 2017: aTyr Pharma Announces Leadership Transition 41
Apr 10, 2017: aTyr Pharma Announces Appointment of Timothy P. Coughlin to its Board of Directors 42
Apr 03, 2017: aTyr Pharma Announces Appointment of Jeffery S. Hatfield to its Board of Directors 43
Product News 44
12/21/2017: aTyr Pharma Announces Poster Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium 44
09/27/2017: aTyr Pharma to Present Final Data for Resolaris Phase 1b/2 Trial in Patients with Early-Onset Facioscapulohumeral Muscular Dystrophy at the 22nd International Annual Congress of the World Muscle Society 45
05/15/2017: aTyr Pharma Announces Presentations on Interstitial Lung Disease and the iMod.Fc Program at the American Thoracic Society 2017 International Conference and Will Host an Educational Webinar 46
04/24/2017: aTyr Pharma Announces Promising Top-Line Results from Resolaris Phase 1b/2 Clinical Trial in Patients with Early Onset Facioscapulohumeral Muscular Dystrophy 47
04/24/2017: aTyr Pharma Presents Analyses of Resolaris Phase 1b/2 Trial in Patients with Limb Girdle Muscular Dystrophy 2B and Facioscapulohumeral Muscular Dystrophy at the American Academy of Neurology 69th Annual Meeting 48
Product Approvals 49
Mar 03, 2017: aTyr Pharma Receives EMA Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy with Resolaris 49
Feb 28, 2017: aTyr Pharma Receives U.S. FDA Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy with Resolaris 50
Jan 18, 2017: FDA Grants Fast Track Designation for aTyr’s Resolaris to Treat Limb Girdle Muscular Dystrophy 2B and Removes Partial Clinical Hold for Resolaris 51
Clinical Trials 52
Nov 27, 2017: aTyr Pharma Doses First Subjects in Phase 1 Trial of iMod.Fc (ATYR1923) 52
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53

List of Tables
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
aTyr Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
aTyr Pharma Inc, Deals By Therapy Area, 2012 to YTD 2018 9
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
aTyr Pharma Raises USD76 Million in Series E Financing 11
aTyr Pharma Raises US$49 Million In Series D Financing 13
Pangu BioPharma Renews Agreement with Hong Kong University of Science and Technology 14
aTyr Pharma Enters into Agreement with Hong Kong University of Science and Technology, Scripps Research Institute and Stanford University for Human Proteins Discovery 15
aTyr Pharma Plans to Raise up to USD72 Million in Public Offering of Shares 17
aTyr Pharma Raises USD45.8 Million in Private Placement of Shares, Preferred Shares and Warrants 18
aTyr Pharma to Raise up to USD20 Million in Public Offering of Shares 20
aTyr Pharma Raises USD86.3 Million in IPO of Shares 21
aTyr Pharma Inc, Key Competitors 23
aTyr Pharma Inc, Key Employees 24
aTyr Pharma Inc, Subsidiaries 25

List of Figures
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
aTyr Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[aTyr Pharma Inc (LIFE):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Taiwan Power Co Ltd:電力:M&Aディール及び事業提携情報
    Summary Taiwan Power Company Ltd (Taiwan Power) is an integrated state-owned electric utility that offers electricity generation, transmission and distribution services. The utility generates electricity through various fuel resources including thermal, coal, gas, cogeneration and renewable sources. …
  • The Tata Power Company Limited:企業の戦略・SWOT・財務分析
    The Tata Power Company Limited - Strategy, SWOT and Corporate Finance Report Summary The Tata Power Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Air China Limited:企業の戦略・SWOT・財務情報
    Air China Limited - Strategy, SWOT and Corporate Finance Report Summary Air China Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • WB Electronics SA :企業の戦略・SWOT・財務情報
    WB Electronics SA - Strategy, SWOT and Corporate Finance Report Summary WB Electronics SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Lucasfilm Ltd:企業の戦略的SWOT分析
    Lucasfilm Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Opsona Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Opsona Therapeutics Ltd (Opsona) is a drug developing company that conducts research, develops and commercializes new treatment for the autoimmune and inflammatory diseases and cancers. The company's OPN-305 is a humanized antibody used to reduce pro-inflammatory cytokine production that is …
  • CUB Pty Ltd:企業の戦略的SWOT分析
    CUB Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • IP Group Plc (IPO):企業の財務・戦略的SWOT分析
    Summary IP Group Plc (IP Group) is a provider of venture capital, business building and support, networks and recruitment services. The company invests in companies, which comprise early stage to mature businesses from various sectors such as energy and renewables, medical equipment and supplies, ph …
  • Global Cardiovascular Innovation Center-医療機器分野:企業M&A・提携分析
    Summary Global Cardiovascular Innovation Center (GCIC) is a healthcare service provider that offers medical technology services. The organization designs, manufactures and distributes cardiovascular products and technologies. It has an incubator facility to help start up companies in developing adva …
  • Tecomet Inc:医療機器:M&Aディール及び事業提携情報
    Summary Tecomet Inc (Tecomet) is a medical equipment company that manufactures and markets cases, implants and instruments. The company offers various implants which include acetabular cups, femoral heads, femoral stems, poly liners, femoral wraps, patellas, poly inserts, tibia trays, hooks, plates, …
  • Ubisoft Entertainment S.A.:企業の戦略・SWOT・財務分析
    Ubisoft Entertainment S.A. - Strategy, SWOT and Corporate Finance Report Summary Ubisoft Entertainment S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Maruti Suzuki India Ltd (MARUTI):企業の財務・戦略的SWOT分析
    Maruti Suzuki India Ltd (MARUTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Option NV (OPTI):企業の財務・戦略的SWOT分析
    Option NV (OPTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • China Power Clean Energy Development Co Ltd (0735):企業の財務・戦略的SWOT分析
    China Power Clean Energy Development Co Ltd (0735) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • Renaissance Oil Corp (ROE):石油・ガス:M&Aディール及び事業提携情報
    Summary Renaissance Oil Corp (Renaissance Oil), formerly San Antonio Ventures Inc is an oil and gas exploration and development company that acquires and develops high potential shale and mature fields in Mexico. The company utilizes seismic technology and advanced structural interpretation for the …
  • Britannia Pharmaceuticals Ltd:企業の戦略的SWOT分析
    Britannia Pharmaceuticals Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Entravision Communications Corporation (EVC):企業の財務・戦略的SWOT分析
    Entravision Communications Corporation (EVC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …
  • Global Franchise Group LLC:企業の戦略・SWOT・財務分析
    Global Franchise Group LLC - Strategy, SWOT and Corporate Finance Report Summary Global Franchise Group LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Vedanta Resources Plc:企業のM&A・事業提携・投資動向
    Vedanta Resources Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Vedanta Resources Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Saipem SpA:企業の戦略・SWOT・財務分析
    Saipem SpA - Strategy, SWOT and Corporate Finance Report Summary Saipem SpA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆